Related Experiment Videos
Expression of the SART3 antigens in oral cancers
1Department of Oral Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Abstract:
It was previously reported that SART3 is a tumor-rejection antigen recognized by HLA-A24-restricted cytotoxic T lymphocytes (CTLs). This study investigated expression of the SART3 antigen in oral cancer as a candidate of tumor antigens for use in specific immunotherapy. The SART3 antigen was detected in all of the oral cancer cell lines tested, 24 of 31 (77%) oral cancer tissue samples, 0 of 3 oral benign tumors and 0 of 3 normal oral tissues. Oral cancer cell lines had the ability to stimulate IFN-gamma production by the HLA-A24-restricted and SART3-specific CTLs that were established from the peripheral blood mononuclear cells (PBMCs) of an esophageal cancer patient. Therefore, the SART3 antigen could be an appropriate vaccine candidate for a large number of oral cancer patients.
Insights
The SART3 antigen is present in most oral cancers, making it a promising target for immunotherapy. This tumor antigen can stimulate immune responses, suggesting its potential as a vaccine candidate for oral cancer patients.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- SART3 (Squamous Cell Carcinoma Antigen Recognized by T cells 3) is a known tumor-rejection antigen.
- It is recognized by Human Leukocyte Antigen (HLA)-A24-restricted cytotoxic T lymphocytes (CTLs).
Purpose of the Study:
- To investigate the expression of the SART3 antigen in oral cancer.
- To evaluate SART3 as a potential tumor antigen for specific immunotherapy in oral cancer.
Main Methods:
- Detection of SART3 antigen in oral cancer cell lines and tissue samples.
- Assessment of SART3 antigen's ability to stimulate IFN-gamma production by SART3-specific CTLs.
Main Results:
- SART3 was detected in all tested oral cancer cell lines.
- SART3 was found in 77% (24/31) of oral cancer tissue samples.
- SART3 was not detected in benign oral tumors or normal oral tissues.
- Oral cancer cell lines stimulated IFN-gamma production by SART3-specific CTLs.
Conclusions:
- SART3 is frequently expressed in oral cancer, distinguishing it from normal tissues.
- SART3-specific CTLs can be stimulated by oral cancer cells, indicating immune recognition.
- SART3 is a potential vaccine candidate for oral cancer immunotherapy.